|
|
|
|
Phase-III study shows Lucentis improves vision in branch retinal vein occlusion
Roche announced that the phase-III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with...
|
|
|
CIO Profiles: Chad A. Eckes, CIO Of Cancer Treatment Centers Of America
Career Track Chad A.Eckes CIO, Cancer Treatment Centers of America How long at current company: 3-1/2 years Career accomplishment I'm most proud of: We completed an implementation for electronic medical records across multiple times zones...
|
|
|
A structural investigation of corneal graft failure in suspected recurrent keratoconus
This work has been presented in part at the 2008 British Society for Matrix Biology conference and the 2009 Association for Research in Vision and Ophthalmology conference S Hayes1, R Young1, C Boote1, N Hawksworth2, Y Huang3 and K M...
|
|
|
Jul 2, 2009
-- Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months...
|
|
|
UPDATE 1-Roche's Lucentis found to curb retinal occlusion
LOS ANGELES, July 2 (Reuters) - Monthly injections of Roche Holding AG's Lucentis can significantly improve sight in people with retinal vein occlusion, which leads to vision loss, according to research released by the company's...
|
|
|
20/20: Surgery can let you see like a child again
Durham, N.C.Improvements to cataract surgery and lenses can not only help people see more clearly, but can also help solve their lifelong vision problems and let them ditch their glasses. People commonly start experiencing changes...
|
|
|
Vision recovery in human immunodeficiency virus-infected patients with optic neuropathy treated with highly ac
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Indian Journal of Ophthalmology, 07/02/09 Print Save in My Library Free Full Text Babu et al.- Improvement was documented in all three patients for visual...
|
|
|
Roche/Genentech to seek a new approval for Lucentis
Roches Genentech unit has presented promising data which it hopes will result in an approval for a second indication of the sight drug Lucentis.Genentech said that the findings from the Phase III study BRAVO showed that Lucentis ...
|
|
|
East Africa: Swine Flu Cases Confirmed in the Region
Kigali Two member-states of the East African Community, Kenya and Uganda have confirmed cases of influenza A, H1N1 virus popularly known as swine flu.Quoting Ugandan media, the first case of the deadly disease was diagnosed on Wednesday...
|
|
|
Swine Flu cases confirmed in the region
Two member-states of the East African Community, Kenya and Uganda have confirmed cases of influenza A, H1N1 virus popularly known as swine flu.Quoting Ugandan media, the first case of the deadly disease was diagnosed on Wednesday while...
|
|
|
UPDATE 1-Roche says Lucentis improves patients' vision
ZURICH, July 2 (Reuters) - Monthly injections of Lucentis can significantly improve sight in people with retinal vein occlusion, which leads to vision loss, according to a Phase III study by Roche Holding AG's Genentech unit.The...
|
|
|
Genentech's Phase III retinal vein occlusion trial meets endpoint
(Datamonitor via COMTEX) -- DNA | Quote | Chart | News | PowerRating -- Genentech, a biotechnology company, has reported that the Phase III study Bravo showed Lucentis improved vision, as measured by the primary endpoint of mean change...
|
|
|
Dr. Chuck named chairman at Einstein, Montefiore
Source: Ophthalmology Times E-News Email|Print| Del.icio.us Digg Reddit Facebook |Save|License New YorkRoy S.Chuck, MD, PhD, has been appointed chairman of ophthalmology and visual sciences at Albert Einstein College of Medicine of...
|
|
|
EURLack of visionEUR still holding back PBC, despite increased commitment
A poll by the Kings Fund and NHS Alliance reported that commitment to PBC has increased in the past two years, but said the policy remained hamstrung by confusion over roles, low engagement among clinicians, and a lack of clarity over...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
Study Showed Early and Sustained Improvement in Vision Through Six Months -- ) SOUTH SAN FRANCISCO, Calif., Jul 02, 2009 (BUSINESS WIRE) -- Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis(R) ...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
-- Study Showed Early and Sustained Improvement in Vision Through Six Months -- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection)...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
BusinessWire - Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis(R) (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis(R) (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
Companies mentioned in this article: Genentech, Inc.SOUTH SAN FRANCISCO, Calif. -- (BUSINESSWIRE) -- Genentech, Inc. announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
- Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months,...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch R
Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months,...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
-- BRAVO evaluated the safety and efficacy of six monthly injections of Lucentis compared to monthly sham injections.The two doses of Lucentis studied showed a statistically significant improvement in best-corrected visual acuity (the...
|
|
|
How plants' antioxidants slow prostate cancer, sight loss
More evidence is emerging why the same plant extract could be used to treat several diseases.CHUKWUMA MUANYA examines how antioxidants in plant extracts slow the progression of prostate cancer and sight loss, as well as boost endurance in...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
-- Study Showed Early and Sustained Improvement in Vision Through Six Months -- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul 2, 2009 - Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab...
|
